close
Edit Metric
Company
Value
Source
Source URL
Notes
Cancel
 
close
Edit  |  History
Details
Company:
Value :
Source:
Source URL:
Notes:
 
Feedback  |  FAQ
Get involved

Add a New Bulls Reason
Company: 3SBio (SSRX)
Current price:
Headline: (100 character max)
Analysis:
Cancel
0%
agree
0 votes

edit "Leading biotech company, with Amgen-like product"

Top Contributor: George Spritzer | Created when SSRX was $8.67 | Edit | History

SSRX is one of the leading bio-technology firms in China. Their leading product is EPIAO which is the number one EPO product (anemia treatment) in China. It is a copycat version of Amgen's (AMGN) Epogen, and sells for a much lower price (about 25% of Epogen's cost). In 2007, EPIAO sales were up 22.6% in US$ terms, and year-to-year earnings were up 14.6%. EPIAO sales were 65% of SSRX total revenues in the fourth quarter.

Their second leading product is TPIAO which was developed in-house and is a cancer therapy drug. In 2007, sales were up 168.3% over 2006. TPIAO sales were 23.9% of total sales for full year 2007. SSRX has a patent on TPIAO, so its margins are higher than for EPIAO.

(100 character max) Cancel
0%
agree
0 votes

edit Leading biotech company, with Amgen-like product

Top Contributor: George Spritzer | Created when SSRX was $8.67 | Edit | History

SSRX is one of the leading bio-technology firms in China. Their leading product is EPIAO which is the number one EPO product (anemia treatment) in China. It is a copycat version of Amgen's (AMGN) Epogen, and sells for a much lower price (about 25% of Epogen's cost). In 2007, EPIAO sales were up 22.6% in US$ terms, and year-to-year earnings were up 14.6%. EPIAO sales were 65% of SSRX total revenues in the fourth quarter.

Their second leading product is TPIAO which was developed in-house and is a cancer therapy drug. In 2007, sales were up 168.3% over 2006. TPIAO sales were 23.9% of total sales for full year 2007. SSRX has a patent on TPIAO, so its margins are higher than for EPIAO.

(100 character max) Cancel
The Shelf
Contributions
Help make Wikinvest better! Learn how to get involved. And create an account to build your reputation.
Did you know…?
Bookmarks
Worried about pump and dump?
We review changes
for stock spam
» read more
Want to make Wikinvest better?
We need your help,
contribute today
» learn how
Do you write software?
We are recruiting
the best engineers
» view jobs
Like Wikinvest?
Spread the word —
Tell your friends!
» spread the word
Wikinvest © 2006, 2007, 2008. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.
Powered by MediaWiki